Board of directors
Herbert Heyneker - Chairman
- Biotech business pioneer
After earning his PhD from Leiden University in Holland, Herbert Heyneker moved in 1975 to San Francisco to take a postdoc in Herbert Boyer’s UCSF lab where he was involved in gene splicing and somatostatin research. Soon afterward, he joined Genentech as one of the company’s first scientists. In 1984 he moved to Genencor, Genentech spinoff to become VP of R&D. He has held positions with Eos Biotechnology, ProtoGene Laboratories, GlycoGen and Genencor. He also served on the board of directors for GenPharm and Guava Technologies in the US and in the Netherlands, IntroGene (acquired by Crucell), Pharming, Pepscan and Prosensa. He is an author on more than 50 peer-reviewed papers and an inventor on more than 30 US patents.
Paul Vulto - Executive Director
As co-CEO and co-founder of MIMETAS, Paul closed deals with most top-10 pharma companies, secured series A and B investment rounds and enabled mass production & global marketing of OrganoPlates. Before founding MIMETAS, Paul worked for the high-tech company Silicon Biosystems in Bologna, the Institute for Microsystems Engineering (IMTEK) at the University of Freiburg and the Leiden Academic Centre for Drug Research, Leiden University. Paul holds a cum laude masters degree in Biomedical Engineering and a cum laude Ph.D. degree in Microsystems Engineering.
Jos Joore - Executive Director
Jos Joore is a biotech entrepreneur with over 20 years of executive level bio-business experience and eight years in bioscience research. As co-CEO and co-founder of MIMETAS, Jos closed deals with more than half of the top-50 pharmaceutical companies, secured series A and B investment rounds and enabled mass production and global sales & marketing of OrganoPlates® and better predictive, human organ-on-a-chip models. Previously, he has held managerial positions in a variety of biotech companies, including Pepscan, SkylineDx and Kreatech (currently part of Leica Biosciences). Jos holds a masters degree in Biology, a Ph.D. in Developmental Biology and a cum laude masters degree in Business Marketing.
André Hoekema - Non-Executive Director
- Representing Oost NL and Zeeuws InvesteringsFonds
- Pharma dealmaker
- Corporate biotech business
- Sales and distribution
Dr. Hoekema is Chief Business Officer of Galapagos. He joined Galapagos from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe. He brings 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and MOGEN (Research and Project Management) and Genentech, Inc (R&D). Dr. Hoekema has a PhD degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the US.
Christoph Waer - Non-Executive Director
- Representing Korys
Christoph is a senior investment manager at Korys, focusing on the fund’s life science investments. In this capacity, he currently represents Korys on the board of Agendia, Bluebee, Genae, MyCartis, MRM Technologies and reMYND. Prior to Korys, Christoph was active in investment banking (corporate finance - BNP Paribas Fortis Bank) and biotech (iPierian). Christoph earned a MSc in Bioengineering, a MSc in Applied Economics at the KU Leuven and holds a MSc in International Management from the IAE Aix-en-Provence.
Edward Willems - Non-Executive Director
Edward is a business developer for over 25 years in global finance (Paris, London, Hong-Kong, Tokyo and Singapore). He is the founder of Ginward and its sister company Gold Nest Private Capital, whose funds make direct investments in Europe and Asia-Pacific in the fields of Life Sciences, Environmental Sciences and IoT. A Fellow of the Institute of Directors in London, he holds a Masters in Electronic Engineering and a Diplôme d’Ingénieur des Télécommunications. Prior to his current position, he was the Deputy Global Head of Markets and Member of the Committee for International Group Strategy at Crédit Agricole, France’s second-largest banking group, which he joined in 1993.
Eric van der Putten - Non-Executive Director
- Representing Aglaia
Eric has 30 years of clinical research experience and started his career in 1983 as Head Trial Department of the Comprehensive Cancer Center Amsterdam. Between 1990 and 2000, he held several positions at companies specialized in electronic data collection systems for clinical research, as well as market research for the pharmaceutical industry. In 2000 Eric joined NDDO Oncology, a spin-off company of the European Organisation for Research and Treatment of Cancer (EORTC), where he was COO and CEO. After the acquisition of NDDO Oncology by INC Research in 2005, he became Vice President Oncology for Europe at INC Research, now Syneos Health. Eric is one of the co-founders of SMS-oncology, a specialized oncology CRO established in 2007 where he worked as COO and CEO. In 2013 Eric became partner at Aglaia, a venture capital firm with a 100% focus on oncology therapeutics and diagnostics. Furthermore, Eric is director at Modra Pharmaceuticals, an Aglaia portfolio company.